China channel feed – Endpoints News

China channel feed

Forget Nasdaq. China’s biotechs with blockbuster IPO dreams are switching focus to Hong Kong

8 years ago

Hong Kong clears way for pre-revenue biotech IPOs, plans to accept listing applications by May

8 years ago

Endpoints' China coverage is getting deeper. Announcing our partnership with PharmCube, the leading Chinese biopharma data provider

8 years ago

Publisher's note

As gene editing explodes, a new report from Goldman says Chinese groups are seizing the lead on CRISPR and CAR-T studies

8 years ago

After a makeover and hiring spree, China's drug agency is romping and stomping on new reviews and approvals

8 years ago

Chinese oncology startup Adagene closes $50M Series C led by Sequoia Capital

8 years ago

China's biotech pipeline is brimming with PD-1/L1 checkpoints. Are they really needed?

8 years ago

Shakeup at China FDA after chief vaults to the helm of a regulatory umbrella group, new agency head named

8 years ago

China stocks the new trend? Loncar launches index

8 years ago

Bye CFDA: China's drug regulator to take new shape in major government restructuring

8 years ago

Hua Medicine plans to join trendy Hong Kong IPO club, pitching an offering of up to $400M -- reports

8 years ago

Juno, WuXi JV gets a $90M round as China’s CAR-T pioneers fly high with fresh cash

8 years ago

Oxford Vacmedix moves cancer vaccines forward with $12.5M from South Korea, China

8 years ago

Chinese medicine player Tasly considers Hong Kong IPO for its biotech arm: report

8 years ago

Novartis’ oncology research chief in China jumps to upstart EpimAb in Shanghai

8 years ago

A week of UK deals exemplifies China’s growing role in global biotech investment

8 years ago

Billion-dollar biosim maker mulls $500M Hong Kong IPO

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Fast-growing Shanghai Pharma to plant foot in San Diego, hunting deals in US and Europe

8 years ago

In a breakthrough, Chinese researchers clone monkeys hoping to provide better disease models

8 years ago

China's KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly

8 years ago

Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio

8 years ago

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

8 years ago

AstraZeneca teams with China-owned fund to launch a new biopharma drug development company

8 years ago

First page Previous page 25 26 272829 30 Next page Last page